With subpar sales for Leqembi, Eisai delays Alzheimers patient goal deadline
Leqembi, Alzheimer’s Disease, Eisai, subpar sales
After Incyte’s commercial buy, Novartis shells out 2.7B for cancer specialist MorphoSys
Importal, MorphoSys, Acquisition (action), Incyte
UPDATE: Vertex beats own record in cystic fibrosis as next-gen treatment goes up against Trikafta
Cystic Fibrosis, Trikafta, vanza, Vertex, next-gen, Records
Sanofi guarantees employees one year of salary and support after cancer diagnosis
Workers, Malignant Neoplasms, sanofi, Affecting, Cancer Diagnosis
J&J’s Nipocalimab Demonstrates Positive Phase III and Phase II Results in Autoimmune Disorders
Nipocalimab, Sjogren’s Syndrome, Johnson and Johnson, Autoimmune Diseases, Myasthenia Gravis, Generalized, Clinical Research, Erythroblastosis, Fetal
Lilly reports mid-stage win for tirzepatide in fatty liver disease
tirzepatide, Nonalcoholic Steatohepatitis, liver scarring, Lilly reports, MASH, Clinical Trials
GSK details Blenreps PhIII combo winas it hopes to stage a turnaround in multiple myeloma
Multiple Myeloma, Blenrep, turnaround, GSK’s, Progression-Free Survival, Combined
4DMT’s Gene Therapy Reduces Eylea Injections, Advancing Plans for Phase 3 Trial in Wet AMD
Glycogen storage disease type II, 4DMT, gene therapy, Trial Phase
Updated: Novo Holdings pays $16.5B to take Catalent private and sells three manufacturing sites to Novo Nordisk
Holdings, Nordisk, deal, Acquisition (action), Investments
Takeda Appoints Former CRISPR CMO Phuong Khanh (PK) Morrow to Lead Oncology R&D Amidst Pipeline Pruning
Clustered Regularly Interspaced Short Palindromic Repeats, PK